FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890462887> ?p ?o ?g. }

• W2890462887 endingPage "1964" @default.
• W2890462887 startingPage "1959" @default.
• W2890462887 abstract "Anthracycline is a commonly prescribed antineoplastic agent. As a consequence of the growing number of cancer survivors, the incidence of anthracycline-induced cardiotoxicity is increasing. However, the optimal primary preventive strategy is lacking. Therefore, we conducted a meta-analysis of all randomized controlled trials to evaluate the efficacy of carvedilol for the primary prevention of anthracycline-induced cardiotoxicity. A comprehensive search of electronic databases was conducted. The primary and secondary outcomes were the occurrence of low left ventricular ejection fraction, and the absolute change in left ventricular ejection fraction (LVEF), respectively. We calculated the odds ratios for the primary outcome and the weighted mean differences for the secondary outcomes using a random-effects model. We included 8 randomized controlled trials (633 total patients). Our results showed significantly reduced rates of low LVEF favoring the carvedilol group (3.2% vs 5.8%; odds ratios: 0.42; 95% confidence interval: 0.18 to 0.99; p = 0.05). Furthermore, there were significantly smaller reductions in LVEF in carvedilol-treated patients than in placebo-treated patients (mean differences: 2.41%; 95% confidence interval: 0.01 to 4.81; p = 0.05). In conclusion, prophylactic administration of carvedilol in anthracycline-treated cancer patients may reduce the early onset of left ventricular dysfunction compared with placebo. Anthracycline is a commonly prescribed antineoplastic agent. As a consequence of the growing number of cancer survivors, the incidence of anthracycline-induced cardiotoxicity is increasing. However, the optimal primary preventive strategy is lacking. Therefore, we conducted a meta-analysis of all randomized controlled trials to evaluate the efficacy of carvedilol for the primary prevention of anthracycline-induced cardiotoxicity. A comprehensive search of electronic databases was conducted. The primary and secondary outcomes were the occurrence of low left ventricular ejection fraction, and the absolute change in left ventricular ejection fraction (LVEF), respectively. We calculated the odds ratios for the primary outcome and the weighted mean differences for the secondary outcomes using a random-effects model. We included 8 randomized controlled trials (633 total patients). Our results showed significantly reduced rates of low LVEF favoring the carvedilol group (3.2% vs 5.8%; odds ratios: 0.42; 95% confidence interval: 0.18 to 0.99; p = 0.05). Furthermore, there were significantly smaller reductions in LVEF in carvedilol-treated patients than in placebo-treated patients (mean differences: 2.41%; 95% confidence interval: 0.01 to 4.81; p = 0.05). In conclusion, prophylactic administration of carvedilol in anthracycline-treated cancer patients may reduce the early onset of left ventricular dysfunction compared with placebo." @default.
• W2890462887 created "2018-09-27" @default.
• W2890462887 creator A5009068237 @default.
• W2890462887 creator A5010571732 @default.
• W2890462887 creator A5026680848 @default.
• W2890462887 creator A5037647594 @default.
• W2890462887 creator A5047254904 @default.
• W2890462887 creator A5048351300 @default.
• W2890462887 creator A5067050666 @default.
• W2890462887 creator A5071505108 @default.
• W2890462887 creator A5079127024 @default.
• W2890462887 creator A5087207098 @default.
• W2890462887 date "2018-12-01" @default.
• W2890462887 modified "2023-10-17" @default.
• W2890462887 title "Meta-Analysis of Carvedilol for the Prevention of Anthracycline-Induced Cardiotoxicity" @default.
• W2890462887 cites W1492360552 @default.
• W2890462887 cites W1975300821 @default.
• W2890462887 cites W1983953026 @default.
• W2890462887 cites W1998141986 @default.
• W2890462887 cites W2088599677 @default.
• W2890462887 cites W2091238429 @default.
• W2890462887 cites W2094415834 @default.
• W2890462887 cites W2112196039 @default.
• W2890462887 cites W2119340816 @default.
• W2890462887 cites W2124651844 @default.
• W2890462887 cites W2129791669 @default.
• W2890462887 cites W2140182328 @default.
• W2890462887 cites W2161374186 @default.
• W2890462887 cites W2280485006 @default.
• W2890462887 cites W2427094903 @default.
• W2890462887 cites W2587882014 @default.
• W2890462887 cites W2602419817 @default.
• W2890462887 cites W2770047542 @default.
• W2890462887 cites W2781525129 @default.
• W2890462887 cites W2784291607 @default.
• W2890462887 cites W2789300675 @default.
• W2890462887 cites W4238907867 @default.
• W2890462887 cites W95894433 @default.
• W2890462887 doi "https://doi.org/10.1016/j.amjcard.2018.08.039" @default.
• W2890462887 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30292333" @default.
• W2890462887 hasPublicationYear "2018" @default.
• W2890462887 type Work @default.
• W2890462887 sameAs 2890462887 @default.
• W2890462887 citedByCount "48" @default.
• W2890462887 countsByYear W28904628872019 @default.
• W2890462887 countsByYear W28904628872020 @default.
• W2890462887 countsByYear W28904628872021 @default.
• W2890462887 countsByYear W28904628872022 @default.
• W2890462887 countsByYear W28904628872023 @default.
• W2890462887 crossrefType "journal-article" @default.
• W2890462887 hasAuthorship W2890462887A5009068237 @default.
• W2890462887 hasAuthorship W2890462887A5010571732 @default.
• W2890462887 hasAuthorship W2890462887A5026680848 @default.
• W2890462887 hasAuthorship W2890462887A5037647594 @default.
• W2890462887 hasAuthorship W2890462887A5047254904 @default.
• W2890462887 hasAuthorship W2890462887A5048351300 @default.
• W2890462887 hasAuthorship W2890462887A5067050666 @default.
• W2890462887 hasAuthorship W2890462887A5071505108 @default.
• W2890462887 hasAuthorship W2890462887A5079127024 @default.
• W2890462887 hasAuthorship W2890462887A5087207098 @default.
• W2890462887 hasConcept C121608353 @default.
• W2890462887 hasConcept C126322002 @default.
• W2890462887 hasConcept C142724271 @default.
• W2890462887 hasConcept C156957248 @default.
• W2890462887 hasConcept C164705383 @default.
• W2890462887 hasConcept C168563851 @default.
• W2890462887 hasConcept C204787440 @default.
• W2890462887 hasConcept C27081682 @default.
• W2890462887 hasConcept C2776694085 @default.
• W2890462887 hasConcept C2776802502 @default.
• W2890462887 hasConcept C2778198053 @default.
• W2890462887 hasConcept C2778233292 @default.
• W2890462887 hasConcept C2780591200 @default.
• W2890462887 hasConcept C44249647 @default.
• W2890462887 hasConcept C530470458 @default.
• W2890462887 hasConcept C71924100 @default.
• W2890462887 hasConcept C78085059 @default.
• W2890462887 hasConceptScore W2890462887C121608353 @default.
• W2890462887 hasConceptScore W2890462887C126322002 @default.
• W2890462887 hasConceptScore W2890462887C142724271 @default.
• W2890462887 hasConceptScore W2890462887C156957248 @default.
• W2890462887 hasConceptScore W2890462887C164705383 @default.
• W2890462887 hasConceptScore W2890462887C168563851 @default.
• W2890462887 hasConceptScore W2890462887C204787440 @default.
• W2890462887 hasConceptScore W2890462887C27081682 @default.
• W2890462887 hasConceptScore W2890462887C2776694085 @default.
• W2890462887 hasConceptScore W2890462887C2776802502 @default.
• W2890462887 hasConceptScore W2890462887C2778198053 @default.
• W2890462887 hasConceptScore W2890462887C2778233292 @default.
• W2890462887 hasConceptScore W2890462887C2780591200 @default.
• W2890462887 hasConceptScore W2890462887C44249647 @default.
• W2890462887 hasConceptScore W2890462887C530470458 @default.
• W2890462887 hasConceptScore W2890462887C71924100 @default.
• W2890462887 hasConceptScore W2890462887C78085059 @default.
• W2890462887 hasFunder F4320306493 @default.
• W2890462887 hasIssue "11" @default.
• W2890462887 hasLocation W28904628871 @default.
• W2890462887 hasLocation W28904628872 @default.

• next